Zovegalisib Market Summary

Key Factors Driving Zovegalisib Growth

1. Mutant-selective PI3Kα inhibition could provide a differentiated efficacy–safety profile: Zovegalisib is an oral, mutant-selective PI3Kα inhibitor designed to preferentially inhibit PIK3CA-mutant tumor cells while sparing wild-type PI3Kα signaling in normal tissues. This is commercially important because hyperglycemia and other metabolic toxicities have historically limited PI3K-pathway therapies. In the ReDiscover program, the safety profile has generally been manageable; notably, the Phase III dose of 400 mg twice daily with food produced 0% grade 3 hyperglycemia, despite 47% of patients being pre-diabetic in the triplet dataset.

2. Large biomarker-defined breast-cancer opportunity: PIK3CA alterations occur in approximately 40% of HR-positive/HER2-negative advanced breast cancers, creating a substantial biomarker-defined population for PI3Kα-targeted treatment. Zovegalisib is being developed particularly for PIK3CA-mutated HR+/HER2− metastatic breast cancer, where endocrine resistance and progression after CDK4/6 inhibitors create a significant need for new targeted options.

3. Strong Phase I/II efficacy in heavily pretreated patients: Zovegalisib + fulvestrant produced a median PFS of 11.1 months at the selected Phase III dose (400 mg BID fed) in heavily pretreated patients with PI3Kα-mutated HR+/HER2− metastatic breast cancer. Importantly, efficacy was similar between kinase-domain and non-kinase-domain PIK3CA mutations, with median PFS of 11.2 and 11.0 months, respectively. Earlier 2025 data showed a median PFS of 10.3 months overall and an ORR of 39% among patients with measurable disease; in second-line patients, ORR reached 47% with median PFS of 11.4 months.

4. FDA Breakthrough Therapy designation strengthens the regulatory opportunity: In February 2026, the FDA granted Breakthrough Therapy designation to zovegalisib + fulvestrant for adults with PIK3CA-mutant HR+/HER2− locally advanced/metastatic breast cancer after recurrence or progression following a CDK4/6 inhibitor. This designation can facilitate more intensive FDA interaction and potentially expedite development and review if efficacy is confirmed. Relay is currently conducting the Phase III ReDiscover-2 trial in this population.

5. Expansion into first-line treatment through combination with atirmociclib could substantially enlarge the opportunity: Relay selected zovegalisib + atirmociclib + an aromatase inhibitor as its preferred triplet for frontline development. In heavily pretreated, median-third-line patients, the triplet produced an ORR of 44%, with tumor reduction in 85% (29/34) of evaluable patients. Only 2 patients (3%) discontinued zovegalisib because of treatment-related adverse events, while 77% of patients remained on study at the April 2026 data cutoff. Relay plans to initiate a Phase III frontline study in endocrine-sensitive metastatic breast cancer in early 2027, subject to regulatory feedback.

Zovegalisib Recent Developments

In September 2026, X-Chem announced it achieved a major milestone payment under its Research Collaboration and License Agreement with Relay Therapeutics. Zovegalisib originally originated as a starting compound discovered using X-Chem’s DNA-encoded chemical library (DEL) screening platform. The milestone was triggered directly by Relay’s official initiation of its Phase III trials.

“Zovegalisib Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Zovegalisib for potential indication like HER2 negative breast cancer, Lymphatic disorders, Vascular malformations, and Solid tumours in the 7MM. A detailed picture of Zovegalisib’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Zovegalisib for potential indications. The Zovegalisib market report provides insights about Zovegalisib’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Zovegalisib performance, future market assessments inclusive of the Zovegalisib market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Zovegalisib sales forecasts, along with factors driving its market.

Zovegalisib Drug Summary

Zovegalisib (RLY-2608) is an investigational, orally administered, mutant-selective phosphoinositide 3-kinase alpha (PI3Kα) inhibitor developed by Relay Therapeutics for the treatment of PIK3CA-mutated cancers and PIK3CA-driven vascular anomalies. It is designed as an allosteric, pan-mutant and isoform-selective PI3Kα inhibitor, targeting activating mutations in the PIK3CA gene while aiming to spare wild-type PI3Kα and other PI3K isoforms. By inhibiting mutant PI3Kα, zovegalisib suppresses aberrant signaling through the PI3K/AKT/mTOR pathway, which can reduce tumor-cell proliferation and survival. Its clinical development has focused particularly on PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer, where it is being evaluated in combination with fulvestrant and other endocrine/CDK-directed therapies. The ongoing Phase III ReDiscover-2 study is evaluating zovegalisib plus fulvestrant against capivasertib plus fulvestrant in patients whose disease has progressed following CDK4/6 inhibitor therapy. Zovegalisib is also being investigated in PIK3CA-related overgrowth spectrum (PROS) and other PIK3CA-driven vascular anomalies, with an ongoing Phase II study evaluating adults and children with these conditions. In May 2026, Relay Therapeutics reported initial Phase II ReInspire data showing a 60% volumetric response rate across tested doses at 12 weeks, alongside symptomatic improvement and a safety profile considered supportive of chronic dosing. Zovegalisib remains investigational and is not currently approved for routine clinical use. The report provides Zovegalisib’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Zovegalisib Market Report

The report provides insights into:

• A comprehensive product overview including the Zovegalisib MoA, description, dosage and administration, research and development activities in potential indication like HER2 negative breast cancer, Lymphatic disorders, Vascular malformations, and Solid tumours.
• Elaborated details on Zovegalisib regulatory milestones and other development activities have been provided in Zovegalisib market report.
• The report also highlights Zovegalisib‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Zovegalisib market report also covers the patents information, generic entry and impact on cost cut.
• The Zovegalisib market report contains current and forecasted Zovegalisib sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Zovegalisib market report also features the SWOT analysis with analyst views for Zovegalisib in potential indications.

Methodology

The Zovegalisib market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Zovegalisib Analytical Perspective by DelveInsight

• In-depth Zovegalisib Market Assessment

This Zovegalisib sales market forecast report provides a detailed market assessment of Zovegalisib for potential indication like HER2 negative breast cancer, Lymphatic disorders, Vascular malformations, and Solid tumours in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Zovegalisib sales data uptil 2034.

• Zovegalisib Clinical Assessment

The Zovegalisib market report provides the clinical trials information of Zovegalisib for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Zovegalisib Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Zovegalisib Market Potential & Revenue Forecast

• Projected market size for the Zovegalisib and its key indications
• Estimated Zovegalisib sales potential (Zovegalisib peak sales forecasts)
• Zovegalisib Pricing strategies and reimbursement landscape

Zovegalisib Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Zovegalisib Market positioning compared to existing treatments
• Zovegalisib Strengths & weaknesses relative to competitors

Zovegalisib Regulatory & Commercial Milestones

• Zovegalisib Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Zovegalisib Clinical Differentiation

• Zovegalisib Efficacy & safety advantages over existing drugs
• Zovegalisib Unique selling points

Zovegalisib Market Report Highlights

• In the coming years, the Zovegalisib market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Zovegalisib companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Zovegalisib’s dominance.
• Other emerging products for HER2 negative breast cancer, Lymphatic disorders, Vascular malformations, and Solid tumours are expected to give tough market competition to Zovegalisib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Zovegalisib in potential indications.
• Analyse Zovegalisib cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Zovegalisib sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Zovegalisib in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Zovegalisib? How strong is Zovegalisib’s clinical and commercial performance?
• What is Zovegalisib’s clinical trial status in each individual indications such as HER2 negative breast cancer, Lymphatic disorders, Vascular malformations, and Solid tumours and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Zovegalisib Manufacturers?
• What are the key designations that have been granted to Zovegalisib for potential indications? How are they going to impact Zovegalisib’s penetration in various geographies?
• What is the current and forecasted Zovegalisib market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Zovegalisib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Zovegalisib for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Zovegalisib? What is the duration of therapy and what are the geographical variations in cost per patient?